{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:10:21Z","timestamp":1784059821974,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jim.2020.112736","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T08:02:43Z","timestamp":1578384163000},"page":"112736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs"],"prefix":"10.1016","volume":"479","author":[{"given":"Michael S.","family":"Seaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslawa","family":"Bilska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Ghantous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia C.","family":"LaBranche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne J.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Sarzotti-Kelsoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2020.112736_bb0005","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0015","series-title":"Implementation of a Three-Tiered Approach To Identify And Characterize Anti-Drug Antibodies Raised Against Hiv-Specific Broadly Neutralizing Antibodies","author":"Bharadwaj","year":"2019"},{"key":"10.1016\/j.jim.2020.112736_bb0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0035","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","article-title":"Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0045","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0050","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat. Commun. Infect. Dis."},{"key":"10.1016\/j.jim.2020.112736_bb0055","series-title":"Immunogenicity Assessment for Therapeutic Protein Products","author":"Guidance for Industry","year":"2014"},{"key":"10.1016\/j.jim.2020.112736_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","article-title":"Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics","volume":"321","author":"Gupta","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2020.112736_bb0065","series-title":"U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER)","author":"Immunogenicity Testing of Therapeutic Protein Products - Developing and Validating Assays for Anti-Drug Antibody Detection","year":"2019"},{"key":"10.1016\/j.jim.2020.112736_bb0070","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0075","article-title":"Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0080","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00498-17","article-title":"Virological control by the CD4-binding site antibody N6 in simian-human immunodeficiency virus-infected rhesus monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2020.112736_bb0085","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0090","article-title":"Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults","author":"Ledgerwood","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jim.2020.112736_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0100","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jim.2020.112736_bb0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jim.2020.112736_bb0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008992","article-title":"Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor","volume":"6","author":"Pegu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jim.2020.112736_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120451","article-title":"Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques","volume":"10","author":"Rosenberg","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2020.112736_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212649","article-title":"Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques","volume":"14","author":"Rosenberg","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2020.112736_bb0130","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2020.112736_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000067","article-title":"Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials","volume":"6","author":"Sarzotti-Kelsoe","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.jim.2020.112736_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2020.112736_bb0145","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1128\/JVI.00210-15","article-title":"Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian\/human immunodeficiency virus infection","volume":"89","author":"Saunders","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2020.112736_bb0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0155","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jim.2020.112736_bb0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jim.2020.112736_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","volume":"2016","author":"Song","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jim.2020.112736_bb0170","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","article-title":"Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics","volume":"18","author":"Wu","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2020.112736_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jim.2015.08.002","article-title":"A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays","volume":"426","author":"Zoghbi","year":"2015","journal-title":"J. Immunol. Methods"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920300016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175920300016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:37:58Z","timestamp":1758299878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175920300016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"alternative-id":["S0022175920300016"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2020.112736","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2020.112736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112736"}}